Alpha-synuclein fibril-based mouse model of REM sleep behavior disorder as a prodrome of synucleinopathy
Objective: To investigate whether in wild-type mice, inoculation of α-synuclein (aSyn) preformed fibrils (PFFs) into the sublaterodorsal tegmental nucleus (SLD), a core structure associated with…Investigation of Modifiers of β-Glucocerebrosidase in Cell Models of Parkinson’s Disease
Objective: We firstly aim to identify modifiers of β-glucocerebrosidase (GCase) activity and expression in Parkinson’s disease (PD) relevant cell models. We secondly aim to ascertain…A novel alpha-synuclein gene (SNCA) missense variant in an Austrian familiy with atypical neuropathological features
Objective: To offer clinical, genetic and neuropathological information in a novel alpha-synuclein gene (SNCA) missense variant to further our understanding of synucleinopathies. Background: Around 5–10% of…Utilising multiple murine models to investigate sleep and circadian system dysfunction in PD
Objective: We aimed to investigate the impact of alpha-synuclein aggregation and spreading, and nigrostriatal dopaminergic degeneration on sleep homeostasis and circadian function. Background: Sleep dysfunction…Cinpanemab in Parkinson’s Disease: Imaging and Fluid Biomarker Results from the Phase 2 SPARK Study
Objective: To evaluate the effects of cinpanemab on biomarkers in participants with Parkinson’s disease (PD). Background: SPARK (NCT03318523) was designed to evaluate the safety, pharmacokinetics,…Lateralized Tau Pathology in a Case of Lewy Body Dementia with Corticobasal Syndrome
Objective: To measure bilateral in vivo and postmortem tau pathology in a well-characterized patient presenting with corticobasal syndrome (CBS) due to underlying neocortical stage Lewy…α-synuclein and deficits of membrane trafficking in Parkinson’s Disease
Objective: Aim of the study is to understand the physical and functional relationships between the PD-associated protein α-synuclein and some of the Soluble N-ethylmaleimide-sensitive-factor Attachment…FIRST-IN-MAN CLINICAL TRIAL OF INTRAPUTAMENAL CDNF IN PARKINSON’S DISEASE FINDS A CONSORTED BIOMARKER RESPONSE IN A SUBGROUP OF SUBJECTS
Objective: In the first-in-man clinical study of intermittent intraputamenal monthly infusions of CDNF in subjects with moderately advanced PD, we explored cerebrospinal fluid (CSF) biomarkers…Extensive volume increases sensitivity of alpha-synuclein accumulation in the gastrointestinal tract
Objective: This study aimed to verify whether evaluation of extensive tissue volume increases sensitivity of detecting alpha-synuclein (AS) pathology in the gastrointestinal (GI) tract in…Neurogenetic Traits Outline Vulnerability to Cortical Disruption in Parkinson’s Disease
Objective: In this study, we characterized the brain topological intersection between propagating connectivity networks in healthy controls (HC) and Parkinson’s disease (PD) participants and gene…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 51
- Next Page »